Skip to content

HTFL HTFL Derivative Liabilities - Fair Value

Derivative Liabilities - Fair Value at other companies

Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
Edwards Lifesciences logo
Edwards LifesciencesEW

Other financials

Income statement

See full
Revenue$52.6M+41.3%
Gross profit$42.2M+50.9%
Operating income-$29.5M-68.6%
Net income-$27.4M+15.4%
EPS (diluted)-$0.32+93.9%

Balance sheet

See full
Cash & equivalents$24.4M-78.7%
Total debt$26.3M
Total equity$285.7M+132%
Total assets$344.0M

Cash flow

See full
Operating cash flow-$30.1M-129%
CapEx$1.9M+71.6%
Free cash flow-$32.0M-124%

Valuation

See full
Market cap$2.97B
Enterprise value$2.98B
P/S15.5×

Profitability

See full
Gross margin78.1%+2.4pp
Operating margin-39.7%-4.8pp
Net margin-58.4%-12.1pp
FCF margin-40.1%-2.4pp

Returns & leverage

See full
Return on equity37.1%
Debt / equity0.1×
Current ratio5.6×

Where this comes from

Reported directly by HTFL in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilities.

The official record: HTFL’s 10-K, filed March 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about HTFL's derivative liabilities - fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is HTFL's derivative liabilities - fair value?
HTFL (HTFL) reported derivative liabilities - fair value of $0 in Q4 2025.
What does derivative liabilities - fair value mean?
This metric represents the total fair market value of all derivative contracts currently in a liability position for the institution. It reflects the potential cash outflow required if these contracts were settled at the current reporting date. Monitoring this value is essential for assessing the bank's exposure to market volatility and counterparty risk.